


PHARMACEUTICAL 2018

IVERIC bio Inc. Rank 155 of 342







PHARMACEUTICAL 2018

IVERIC bio Inc. Rank 155 of 342



The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 161% points. The greatest weakness of IVERIC bio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 69% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	171,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,535
Liabilities, Non-Current	0
Other Assets	3,553
Other Compr. Net Income	212
Other Expenses	-4,712
Other Liabilities	125,000
Other Net Income	211,465
Other Revenues	0
Property and Equipment	518
Research and Development	66,289
Selling, General and Administrative Expense	35,683

Output Variable	Value in 1000 USD
Assets	175,576
Liabilities	137,535
Expenses	97,260
Revenues	0
Stockholders Equity	38,041
Net Income	114,205
Comprehensive Net Income	114,311
Economic Capital Ratio	115%

